logo
RETROVIRAL DELIVERY OF VIRAL INTERLEUKIN-10 INTO MYELOID DENDRITIC CELLS MARKEDLY INHIBITS THEIR ALLOSTIMULATORY ACTIVITY AND PROMOTES THE INDUCTION OF T-CELL HYPORESPONSIVENESS1,2
SYNERGISTIC EFFECTS OF MYCOPHENOLATE MOFETIL AND SIROLIMUS IN PREVENTION OF ACUTE HEART, PANCREAS, AND KIDNEY ALLOGRAFT REJECTION AND IN REVERSAL OF ONGOING HEART ALLOGRAFT REJECTION IN THE RAT1,2
LONG-TERM COMPOSITE TISSUE ALLOGRAFT SURVIVAL IN A PORCINE MODEL WITH CYCLOSPORINE/MYCOPHENOLATE MOFETIL THERAPY1,2
SYSTEMIC ADMINISTRATION OF ANTI-INTERLEUKIN-10 ANTIBODY PROLONGS ORGAN ALLOGRAFT SURVIVAL IN NORMAL AND PRESENSITIZED RECIPIENTS1,2
CENTRAL NERVOUS SYSTEM LESIONS IN LIVER TRANSPLANT RECIPIENTS
PREVENTION AND PREEMPTIVE THERAPY OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE IN PEDIATRIC LIVER RECIPIENTS1
HEPATITIS C INFECTION IN PATIENTS UNDERGOING LIVER RETRANSPLANTATION1,2
A PROSPECTIVE RANDOMIZED TRIAL OF MYCOPHENOLATE MOFETIL WITH NEORAL OR TACROLIMUS AFTER ORTHOTOPIC LIVER TRANSPLANTATION1,2
COMPARISON OF NEORAL DOSE MONITORING WITH CYCLOSPORINE TROUGH LEVELS VERSUS 2-HR POSTDOSE LEVELS IN STABLE LIVER TRANSPLANT PATIENTS1,2
ASSOCIATION OF CYTOMEGALOVIRUS GENOTYPE WITH GRAFT REJECTION AFTER LIVER TRANSPLANTATION1,2
RANDOMIZED TRIAL OF CYCLOSPORINE MICROEMULSION (NEORAL) VERSUS CONVENTIONAL CYCLOSPORINE IN LIVER TRANSPLANTATION
SERIAL MEASUREMENT OF EPSTEIN-BARR VIRAL LOAD IN PERIPHERAL BLOOD IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS DURING TREATMENT FOR POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE1
OUTCOME OF AUTOIMMUNE HEPATITIS AFTER LIVER TRANSPLANTATION1
PROGNOSIS AFTER PRIMARY RENAL TRANSPLANT FAILURE AND THE BENEFICIAL EFFECTS OF REPEAT TRANSPLANTATION
INFERIOR OUTCOME OF CADAVERIC KIDNEYS PRESERVED FOR MORE THAN 24 HR IN HISTIDINE-TRYPTOPHAN-KETOGLUTARATE SOLUTION1
EXPERIMENTAL TRANSPLANTATION OF SIZE-REDUCED, ADULT KIDNEYS INTO PEDIATRIC RECIPIENTS1,2
PROSPECTIVE PRETRANSPLANT ULTRASOUND SCREENING IN 206 PATIENTS FOR ACQUIRED RENAL CYSTS AND RENAL CELL CARCINOMA1
IMMUNE-ACTIVATION GENE EXPRESSION IN CLINICALLY STABLE RENAL ALLOGRAFT BIOPSIES: MOLECULAR EVIDENCE FOR SUBCLINICAL REJECTION1,2
A RANDOMIZED PROSPECTIVE CONTROLLED TRIAL OF ORAL ACYCLOVIR VERSUS ORAL GANCICLOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS IN HIGH-RISK KIDNEY TRANSPLANT RECIPIENTS1
TRANSPLANTATION OF PEDIATRIC EN BLOC CADAVER KIDNEYS INTO ADULT RECIPIENTS1
DONOR HEPATITIS C VIRUS STATUS DOES NOT ADVERSELY AFFECT SHORT-TERM OUTCOMES IN HCV+ RECIPIENTS IN RENAL TRANSPLANTATION1
DELETERIOUS EFFECTS OF DELAYED GRAFT FUNCTION IN CADAVERIC RENAL TRANSPLANT RECIPIENTS INDEPENDENT OF ACUTE REJECTION1,2,3
THE SHRINKING RENAL REPLACEMENT THERAPY "BREAK-EVEN" POINT1
LONG-TERM RENAL FUNCTION IN NON-HEART-BEATING DONOR KIDNEY TRANSPLANTATION
TRANSPLANTATION RATE OF THE BLOOD GROUP B WAITING LIST IS INCREASED BY USING A2 AND A2B KIDNEYS1
COMPLIANCE AND NONCOMPLIANCE IN PATIENTS WITH A FUNCTIONING RENAL TRANSPLANT: A MULTICENTER STUDY1,2
LOW-DOSE CYCLOSPORINE AND MYCOPHENOLATE MOFETIL IN RENAL ALLOGRAFT RECIPIENTS WITH SUBOPTIMAL RENAL FUNCTION1,2
RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RECEPTOR Fc FUSION PROTEIN THERAPY IN KIDNEY TRANSPLANT RECIPIENTS UNDERGOING OKT3 INDUCTION THERAPY1,2
HISTOPATHOLOGIC FINDINGS FROM 2-YEAR PROTOCOL BIOPSIES FROM A U.S. MULTICENTER KIDNEY TRANSPLANT TRIAL COMPARING TACROLIMUS VERSUS CYCLOSPORINE
HISTOLOGIC GRADING OF ACUTE ALLOGRAFT REJECTION IN PANCREAS NEEDLE BIOPSY
POSTTRANSPLANT INFECTION IN ENTERIC VERSUS BLADDER-DRAINED SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1
A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION1
COMBINED HEART AND KIDNEY TRANSPLANTATION USING A SINGLE DONOR
RISKS AND COSTS OF END-STAGE RENAL DISEASE AFTER HEART TRANSPLANTATION1,2
INTERFERON-α TREATMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RECIPIENTS OF SOLID ORGAN TRANSPLANTS1
EFFECT OF ORAL ACYCLOVIR OR GANCICLOVIR THERAPY AFTER PREEMPTIVE INTRAVENOUS GANCICLOVIR THERAPY TO PREVENT CYTOMEGALOVIRUS DISEASE IN CYTOMEGALOVIRUS SEROPOSITIVE RENAL AND LIVER TRANSPLANT RECIPIENTS RECEIVING ANTILYMPHOCYTE ANTIBODY THERAPY1
DONOR RESTING B CELLS INDUCE INDEFINITE PROLONGATION OF FULLY ALLOGENEIC CARDIAC GRAFTS WHEN DELIVERED WITH ANTI-IMMUNOGLOBULIN-D MONOCLONAL ANTIBODY
FAS-MEDIATED CYTOTOXICITY IS NOT REQUIRED FOR REJECTION OF MURINE NONVASCULARIZED HETEROTOPIC CARDIAC ALLOGRAFTS1,2,3
PREDOMINANT EXPRESSION OF T HELPER 2 CYTOKINES AND ALTERED EXPRESSION OF T HELPER 1 CYTOKINES IN LONG-TERM ALLOGRAFT SURVIVAL INDUCED BY INTRATHYMIC IMMUNE MODULATION WITH DONOR CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX PEPTIDES1,2
PHENOTYPE, FUNCTION, AND IN VIVO MIGRATION AND SURVIVAL OF ALLOGENEIC DENDRITIC CELL PROGENITORS GENETICALLY ENGINEERED TO EXPRESS TGF-β1,2
PURIFIED TRUNCATED RECOMBINANT HLA-B7 MOLECULES ABROGATE CELL FUNCTION IN ALLOREACTIVE CYTOTOXIC T LYMPHOCYTES BY APOPTOSIS INDUCTION1,2
COMPARISON BETWEEN ENZYME-LINKED IMMUNOSORBENT ASSAY AND CYTOTOXIC CROSS-MATCH PROCEDURES FOR DETECTING IgG ANTI-DONOR ANTIBODIES1
LONG-TERM GRAFT SURVIVAL IS IMPROVED IN CADAVERIC RENAL RETRANSPLANTATION BY FLOW CYTOMETRIC CROSSMATCHING1
CAN AN IMMUNOLOGICALLY, NONREACTIVE POTENTIAL ALLOGRAFT RECIPIENT UNDERGO TRANSPLANTATION WITHOUT A DONOR-SPECIFIC CROSSMATCH?1
KIDNEY TRANSPLANTATION WITHOUT A FINAL CROSSMATCH1,2
CLINICAL EXPERIENCE WITH AUTOLOGOUS AND ALLOGENEIC PANCREATIC ISLET TRANSPLANTATION1,2
COSTIMULATION PATHWAYS IN HOST IMMUNE RESPONSES TO ALLOGENEIC HEPATOCYTES1,2
ANNOUNCEMENTS